Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1989 | 1 |
2023 | 2 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for
lancet cafiero
Your search for
Lance Caffiero
retrieved no results
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061371
Free PMC article.
Clinical Trial.
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group.
EMPA-KIDNEY Collaborative Group.
Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4.
Lancet Diabetes Endocrinol. 2024.
PMID: 38061372
Free article.
Clinical Trial.
Item in Clipboard
Essential drugs in a European setting.
Pisacane A, Scarpellino B, Mazzarella G, Cafiero M, Coppola A.
Pisacane A, et al.
Lancet. 1989 Mar 4;1(8636):503-4. doi: 10.1016/s0140-6736(89)91408-6.
Lancet. 1989.
PMID: 2563878
No abstract available.
Item in Clipboard
Cite
Cite